{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:57:46Z","timestamp":1781542666820,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Belantamab mafodotin, bortezomib and dexamethasone (BVd) demonstrated clinical activity in the phase I\/II DREAMM-6 (Arm B) study and significant clinical benefit in the phase III DREAMM-7 study for patients with relapsed\/refractory multiple myeloma (RRMM) and \u22651 prior line of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Population pharmacokinetic-derived Cycle 1 (C1) belantamab mafodotin exposures were used to evaluate exposure-efficacy\/exposure-safety relationships across multiple doses and schedules for benefit-risk assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Belantamab mafodotin C1 exposure was positively associated with response endpoints and grade \u22652\/\u2009\u22653 ophthalmic exam findings (OEFs), but not grade \u22652\/ \u22653 ocular adverse events (oAEs) or best-corrected visual acuity (BCVA) worsening to 20\/50 or worse in both eyes. Probability of very good partial response or better (\u2265VGPR) was higher than grade \u22653 oAEs\/BCVA worsening in both eyes across C1 exposures; efficacy improved at higher C1 exposures without increased OEF risk. Model-based benefit-risk assessment showed a belantamab mafodotin starting dose of 1.9\u2009mg\/kg instead of 2.5\u2009mg\/kg would result in lower probability of \u2265VGPR without reduction in BCVA worsening in both eyes\/grade \u22653 oAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>An initial belantamab mafodotin dose of 2.5\u2009mg\/kg for BVd yields deeper responses with minimal change in safety outcomes versus 1.9\u2009mg\/kg for patients with RRMM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03437-7","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T10:59:54Z","timestamp":1776077994000},"page":"60-68","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7"],"prefix":"10.1038","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2691-9392","authenticated-orcid":false,"given":"Theodoros","family":"Papathanasiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Carreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"McKeown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumita","family":"Roy-Ghanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Eccersley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Kasinathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashita","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5703-8315","authenticated-orcid":false,"given":"Geraldine","family":"Ferron-Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"3437_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","volume":"20","author":"R Montes de Oca","year":"2021","unstructured":"Montes de Oca R, Alavi AS, Vitali N, Bhattacharya S, Blackwell C, Patel K, et al. Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo. Mol Cancer Ther. 2021;20:1941\u201355.","journal-title":"Mol Cancer Ther"},{"key":"3437_CR2","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/imt.15.77","volume":"7","author":"YT Tai","year":"2015","unstructured":"Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7:1187\u201399.","journal-title":"Immunotherapy"},{"key":"3437_CR3","unstructured":"ClinicalTrials.gov. To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed\/Refractory Multiple Myeloma (RRMM) (DREAMM 6). https:\/\/clinicaltrials.gov\/study\/NCT03544281?term=NCT03544281&rank=1. Accessed 2025."},{"key":"3437_CR4","unstructured":"ClinicalTrials.gov. Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed\/Refractory Multiple Myeloma (DREAMM 7). https:\/\/clinicaltrials.gov\/study\/NCT04246047?term=DREAMM-7%20&rank=1. Accessed 2025."},{"key":"3437_CR5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391:393\u2013407.","journal-title":"N Engl J Med"},{"key":"3437_CR6","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/S1470-2045(25)00330-4","volume":"26","author":"V Hungria","year":"2025","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. Lancet Oncol. 2025;26:1067\u201380.","journal-title":"Lancet Oncol"},{"key":"3437_CR7","unstructured":"GSK. Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed\/refractory multiple myeloma. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/blenrep-belantamab-mafodotin-combinations-approved-by-uk-mhra-in-relapsedrefractory-multiple-myeloma\/ Accessed 2025."},{"key":"3437_CR8","unstructured":"GSK. Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of relapsed\/refractory multiple myeloma. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/blenrep-belantamab-mafodotin-combinations-approved-in-japan\/. Accessed 2025."},{"key":"3437_CR9","unstructured":"GSK. Blenrep (belantamab mafodotin) combinations approved in Canada for the treatment of relapsed\/refractory multiple myeloma 2025 [updated July 23, 2025. Available from: https:\/\/ca.gsk.com\/en-ca\/media\/press-releases\/blenrep-belantamab-mafodotin-combinations-approved-in-canada-for-the-treatment-of-relapsedrefractory-multiple-myeloma\/."},{"key":"3437_CR10","unstructured":"GSK. Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed\/refractory multiple myeloma 2025 [updated July 24, 2025. Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/blenrep-belantamab-mafodotin-combinations-approved-in-eu-for-treatment-of-relapsedrefractory-multiple-myeloma\/."},{"key":"3437_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.678634","volume":"11","author":"A Wahab","year":"2021","unstructured":"Wahab A, Rafae A, Mushtaq K, Masood A, Ehsan H, Khakwani M, et al. Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma. Front Oncol. 2021;11:678634.","journal-title":"Front Oncol"},{"key":"3437_CR12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","volume":"8","author":"H Donaghy","year":"2016","unstructured":"Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs. 2016;8:659\u201371.","journal-title":"MAbs"},{"key":"3437_CR13","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/cpt.2409","volume":"110","author":"G Ferron-Brady","year":"2021","unstructured":"Ferron-Brady G, Rathi C, Collins J, Struemper H, Opalinska J, Visser S, et al. Exposure-response analyses for therapeutic dose selection of belantamab mafodotin in patients with relapsed\/refractory multiple myeloma. Clin Pharmacol Ther. 2021;110:1282\u201392.","journal-title":"Clin Pharmacol Ther"},{"key":"3437_CR14","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40262-025-01508-1","volume":"64","author":"T Papathanasiou","year":"2025","unstructured":"Papathanasiou T, Kaullen J, Polireddy K, Chen X, Ho YL, Taylor A, et al. Population pharmacokinetics for belantamab mafodotin monotherapy and combination therapies in patients with relapsed\/refractory multiple myeloma. Clin Pharmacokinet. 2025;64:925\u201342.","journal-title":"Clin Pharmacokinet"},{"key":"3437_CR15","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","volume":"97","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97:1761\u20137.","journal-title":"Haematologica"},{"key":"3437_CR16","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/psp4.12660","volume":"10","author":"C Rathi","year":"2021","unstructured":"Rathi C, Collins J, Struemper H, Opalinska J, Jewell RC, Ferron-Brady G. Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed\/refractory multiple myeloma. CPT Pharmacometrics Syst Pharmacol. 2021;10:851\u201363.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"3437_CR17","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1111\/bcp.14662","volume":"87","author":"S Kawakatsu","year":"2021","unstructured":"Kawakatsu S, Bruno R, K\u00e5gedal M, Li C, Girish S, Joshi A, et al. Confounding factors in exposure\u2013response analyses and mitigation strategies for monoclonal antibodies in oncology. Br J Clin Pharmacol. 2021;87:2493\u2013501.","journal-title":"Br J Clin Pharmacol"},{"key":"3437_CR18","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1002\/cncr.34987","volume":"129","author":"AK Nooka","year":"2023","unstructured":"Nooka AK, Cohen AD, Lee HC, Badros A, Suvannasankha A, Callander N, et al. Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: Final analysis of the DREAMM-2 trial. Cancer. 2023;129:3746\u201360.","journal-title":"Cancer"},{"key":"3437_CR19","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1182\/bloodadvances.2025016949","volume":"9","author":"MV Mateos","year":"2025","unstructured":"Mateos MV, Trudel S, Quach H, Robak P, Beksac M, Pour L, et al. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. Blood Adv. 2025;9:5708\u201319.","journal-title":"Blood Adv"},{"key":"3437_CR20","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1002\/psp4.70119","volume":"14","author":"X Yin","year":"2025","unstructured":"Yin X, Xiong Y, Bi Y, Wei X, Zhao H, Fletcher EP, et al. Evaluation and mitigation of time-dependent confounding effects in conventional exposure-response analyses for oncology drugs. CPT Pharmacometrics Syst Pharmacol. 2025;14:2118\u201327.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"3437_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/psp4.13074","volume":"13","author":"MR Wiens","year":"2024","unstructured":"Wiens MR, French JL, Rogers JA. Confounded exposure metrics. CPT Pharmacometrics Syst Pharmacol. 2024;13:187\u201391.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"3437_CR22","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/cpt.1953","volume":"108","author":"HI Dai","year":"2020","unstructured":"Dai HI, Vugmeyster Y, Mangal N. Characterizing exposure-response relationship for therapeutic monoclonal antibodies in immuno-oncology and beyond: challenges, perspectives, and prospects. Clin Pharmacol Ther. 2020;108:1156\u201370.","journal-title":"Clin Pharmacol Ther"},{"key":"3437_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2023.100433","volume":"37","author":"S Fahmawi","year":"2023","unstructured":"Fahmawi S, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD Jr, Zhan F, et al. Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines. J Cancer Policy. 2023;37:100433.","journal-title":"J Cancer Policy"},{"key":"3437_CR24","first-page":"3","volume":"9","author":"SA Padala","year":"2021","unstructured":"Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci (Basel). 2021;9:3.","journal-title":"Med Sci (Basel)"},{"key":"3437_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01155-y","volume":"14","author":"R Popat","year":"2024","unstructured":"Popat R, Augustson B, Gironella M, Lee C, Cannell P, Patel N, et al. Results from Arm A of Phase 1\/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed\/refractory multiple myeloma. Blood Cancer J. 2024;14:184.","journal-title":"Blood Cancer J"},{"key":"3437_CR26","doi-asserted-by":"publisher","first-page":"8502","DOI":"10.1200\/JCO.2020.38.15_suppl.8502","volume":"38","author":"AK Nooka","year":"2020","unstructured":"Nooka AK, Stockerl-Goldstein K, Quach H, Forbes A, Mateos M-V, Khot A, et al. DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib\/dexamethasone in relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2020;38:8502.","journal-title":"J Clin Oncol"},{"key":"3437_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2020-139332","volume":"136","author":"R Popat","year":"2020","unstructured":"Popat R, Nooka A, Stockerl-Goldstein K, Abonour R, Ramaekers R, Khot A, et al. DREAMM-6: safety, tolerability and clinical activity of belantamab mafodotin (Belamaf) in combination with bortezomib\/dexamethasone (BorDex) in relapsed\/refractory multiple myeloma (RRMM). Blood. 2020;136:19\u201320.","journal-title":"Blood"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03437-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03437-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03437-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:41:43Z","timestamp":1781541703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03437-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7,5]]}},"alternative-id":["3437"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03437-7","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TP, GFB, AM, SRG, FC, XC, LE, RV, and NP are employees of and hold financial equities in GSK.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The DREAMM-6 and DREAMM-7 study protocols were reviewed and approved by institutional review boards or an independent ethics committee at each participating site (detailed previously [\n                      \n                      ,\n                      \n                      ]). The trials were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Patients provided signed, informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}